What colorectal surgeons should know about probiotics: A review

Colorectal Disease

Volumn 17, Issue 10, 2015, Pages 840-848

  Kvasnovsky, C L ^a,b   Bjarnason, I ^a   Papagrigoriadis, S ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FRUCTOSE OLIGOSACCHARIDE; MESALAZINE; PREBIOTIC AGENT; PROBIOTIC AGENT; SYNBIOTIC AGENT; TREVIS; UNCLASSIFIED DRUG; VSL3;

ANTIBIOTIC ASSOCIATED DIARRHEA; ARTICLE; BIFIDOBACTERIUM BIFIDUM; BIFIDOBACTERIUM LONGUM; CLOSTRIDIUM DIFFICILE INFECTION; COLON RESECTION; COLORECTAL SURGERY; CROHN DISEASE; DIVERTICULOSIS; DRUG CONTRAINDICATION; DRUG FORMULATION; DRUG USE; HUMAN; ILEITIS; ILEOSTOMY; INFLAMMATORY BOWEL DISEASE; LACTOBACILLUS JOHNSONII; LACTOBACILLUS PLANTARUM; META ANALYSIS (TOPIC); POSTOPERATIVE PERIOD; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURGEON; DIETARY SUPPLEMENT; DRUG EFFECTS; FEMALE; GASTROINTESTINAL DISEASES; KNOWLEDGE; MALE; MICROBIOLOGY; MICROFLORA; PERIOPERATIVE PERIOD; PROCEDURES; PROGNOSIS; TREATMENT OUTCOME;

COLORECTAL SURGERY; DIETARY SUPPLEMENTS; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; KNOWLEDGE; MALE; MICROBIOTA; PERIOPERATIVE CARE; PROBIOTICS; PROGNOSIS; SURGEONS; TREATMENT OUTCOME;

EID: 84941209875     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/codi.13046     Document Type: Article

References (80)

1. Passariello A, Agricole P, Malfertheiner P. A critical appraisal of probiotics (as drugs or food supplements) in gastrointestinal diseases. Curr Med Res Opin 2014; 30: 1055-64.
2. Venugopalan V, Shriner KA, Wong-Beringer A. Regulatory oversight and safety of probiotic use. Emerg Infect Dis 2010; 16: 1661-5.
3. Starling S. EFSA Calls for Characterisation Work as Probiotic Resubmissions Loom. http://www.nutraingredients.com/Regulation-Policy/EFSA-calls-for-characterisation-work-as-probiotic-resubmissions-loom 2011 (accessed May 2015).
4. Guarner F, Khan AG, Garisch J et al. World gastroenterology organisation global guidelines: probiotics and prebiotics October 2011. J Clin Gastroenterol 2012; 46: 468-81.
5. Saxelin M. Probiotic formulations and applications, the current probiotics market, and changes in the marketplace: a European perspective. Clin Infect Dis 2008; 46(Suppl 2): S76-9; discussion S144-51.
6. Food and Agriculture Organization of the United Nations and World Health Organization Working Group. Guidelines for the Evaluation of Probiotics in Food. FAO/WHO, Rome/Geneva. 2002. http://ftp.fao.org/es/esn/food/wgreport2.pdf (accessed July 2015)
7. Gordon JI. Honor thy gut symbionts redux. Science 2012; 336: 1251-3.
8. Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol 2008; 6: e280.
9. Cummings JH. Microbial digestion of complex carbohydrates in man. Proc Nutr Soc 1984; 43: 35-44.
10. Vanderpool C, Yan F, Polk DB. Mechanisms of probiotic action: implications for therapeutic applications in inflammatory bowel diseases. Inflamm Bowel Dis 2008; 14: 1585-96.
11. Yan F, Cao H, Cover TL et al. Colon-specific delivery of a probiotic-derived soluble protein ameliorates intestinal inflammation in mice through an EGFR-dependent mechanism. J Clin Investig 2011; 121: 2242-53.
12. McFarland L, Elmer GM. Probiotics in Food Safety and Human Health. New York: Marcel Dekker, Inc., 2005.
13. Parvez S, Malik KA, Ah Kang S, Kim HY. Probiotics and their fermented food products are beneficial for health. J Appl Microbiol 2006; 100: 1171-85.
14. Savini M, Cecchini C, Verdenelli MC, Silvi S, Orpianesi C, Cresci A. Pilot-scale production and viability analysis of freeze-dried probiotic bacteria using different protective agents. Nutrients 2010; 2: 330-9.
15. Maynard CL, Elson CO, Hatton RD, Weaver CT. Reciprocal interactions of the intestinal microbiota and immune system. Nature 2012; 489: 231-41.
16. Caselli M, Cassol F, Calo G, Holton J, Zuliani G, Gasbarrini A. Actual concept of "probiotics": is it more functional to science or business? World J Gastroenterol 2013; 19: 1527-40.
17. Timmerman HM, Koning CJ, Mulder L, Rombouts FM, Beynen AC. Monostrain, multistrain and multispecies probiotics - a comparison of functionality and efficacy. Int J Food Microbiol 2004; 96: 219-33.
18. Szajewska H. Advances and limitations of evidence-based medicine - impact for probiotics. Ann Nutr Metab 2010; 57(Suppl): 6-9.
19. Hill C, Guarner F, Reid G et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014; 11: 506-14.
20. Alagozlu H, Karakan T. Probiotics are sensitive microorganisms: Lactobacillus can be affected by stomach acid, antibiotic, and bowel cleansing. Dig Dis Sci 2012; 57: 2477-8; author reply-8.
21. Anderson AD, McNaught CE, Jain PK, MacFie J. Randomised clinical trial of synbiotic therapy in elective surgical patients. Gut 2004; 53: 241-5.
22. Zhu D, Chen X, Wu J et al. [Effect of perioperative intestinal probiotics on intestinal flora and immune function in patients with colorectal cancer]. Nan Fang Yi Ke Da Xue Xue Bao 2012; 32: 1190-3.
23. Zhang JW, Du P, Gao J, Yang BR, Fang WJ, Ying CM. Preoperative probiotics decrease postoperative infectious complications of colorectal cancer. Am J Med Sci 2012; 343: 199-205.
24. Liu Z, Qin H, Yang Z et al. Randomised clinical trial: the effects of perioperative probiotic treatment on barrier function and post-operative infectious complications in colorectal cancer surgery - a double-blind study. Aliment Pharmacol Ther 2011; 33: 50-63.
25. Liu ZH, Huang MJ, Zhang XW et al. The effects of perioperative probiotic treatment on serum zonulin concentration and subsequent postoperative infectious complications after colorectal cancer surgery: a double-center and double-blind randomized clinical trial. Am J Clin Nutr 2013; 97: 117-26.
26. Sadahiro S, Suzuki T, Tanaka A et al. Comparison between oral antibiotics and probiotics as bowel preparation for elective colon cancer surgery to prevent infection: prospective randomized trial. Surgery 2014; 155: 493-503.
27. Stephens JH, Hewett PJ. Clinical trial assessing VSL#3 for the treatment of anterior resection syndrome. ANZ J Surg 2012; 82: 420-7.
28. Lee J-Y, Chu S-H, Jeon JY et al. Effects of 12 weeks of probiotic supplementation on quality of life in colorectal cancer survivors: a double-blind, randomized, placebo-controlled trial. Dig Liver Dis 2014; 46: 1126-32.
29. Chapman JR, Dozois EJ, Wolff BG, Gullerud RE, Larson DR. Diverticulitis: a progressive disease? Do multiple recurrences predict less favorable outcomes? Ann Surg 2006; 243: 876-30; discussion 880-3.
30. Raskin JB, Kamm MA, Jamal MM et al. Mesalamine did not prevent recurrent diverticulitis in phase 3 controlled trials. Gastroenterology 2014; 147: 793-802.
31. Tursi A. Preventing recurrent acute diverticulitis with pharmacological therapies. Ther Adv Chronic Dis 2013; 4: 277-86.
32. Tursi A, Brandimarte G, Elisei W et al. Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease - a double-blind, randomised, placebo-controlled study. Aliment Pharmacol Ther 2013; 38: 741-51.
33. Tursi A, Brandimarte G, Giorgetti GM, Elisei W. Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study. J Clin Gastroenterol 2006; 40: 312-6.
34. Stollman N, Magowan S, Shanahan F, Quigley EM. A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. J Clin Gastroenterol 2013; 47: 621-9.
35. Lahner E, Esposito G, Zullo A et al. High-fibre diet and Lactobacillus paracasei B21060 in symptomatic uncomplicated diverticular disease. World J Gastroenterol 2012; 18: 5918-24.
36. Tursi A, Brandimarte G, Giorgetti GM, Elisei W, Aiello F. Balsalazide and/or high-potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. Int J Colorectal Dis 2007; 22: 1103-8.
37. Mallon P, McKay D, Kirk S, Gardiner K. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2007; (4): Cd005573.
38. Shen B, Fazio VW, Remzi FH et al. Effect of withdrawal of nonsteroidal anti-inflammatory drug use on ileal pouch disorders. Dig Dis Sci 2007; 52: 3321-8.
39. Naidoo K, Gordon M, Fagbemi AO, Thomas AG, Akobeng AK. Probiotics for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2011; (12): Cd007443.
40. Shen J, Zuo ZX, Mao AP. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease, and pouchitis: meta-analysis of randomized controlled trials. Inflamm Bowel Dis 2014; 20: 21-35.
41. Sood A, Midha V, Makharia GK et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2009; 7: 1202-9, 9.e1.
42. Tursi A, Brandimarte G, Papa A et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2010; 105: 2218-27.
43. Rolfe VE, Fortun PJ, Hawkey CJ, Bath-Hextall F. Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2006; (4): Cd004826.
44. Butterworth AD, Thomas AG, Akobeng AK. Probiotics for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2008; (3): Cd006634.
45. Doherty G, Bennett G, Patil S, Cheifetz A, Moss AC. Interventions for prevention of post-operative recurrence of Crohn's disease. Cochrane Database Syst Rev 2009; (4): Cd006873.
46. Veerappan GR, Betteridge J, Young PE. Probiotics for the treatment of inflammatory bowel disease. Curr Gastroenterol Rep 2012; 14: 324-33.
47. Simchuk EJ, Thirlby RC. Risk factors and true incidence of pouchitis in patients after ileal pouch-anal anastomoses. World J Surg 2000; 24: 851-6.
48. Kuisma J, Mentula S, Jarvinen H, Kahri A, Saxelin M, Farkkila M. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther 2003; 17: 509-15.
49. Gionchetti P, Rizzello F, Morselli C et al. High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum 2007; 50: 2075-82; discussion 82-4.
50. Gionchetti P, Calafiore A, Riso D et al. The role of antibiotics and probiotics in pouchitis. Ann Gastroenterol 2012; 25: 100-5.
51. Mimura T, Rizzello F, Helwig U et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004; 53: 108-14.
52. Gionchetti P, Rizzello F, Venturi A et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 305-9.
53. Tomasz B, Zoran S, Jaroslaw W et al. Long-term use of probiotics Lactobacillus and Bifidobacterium has a prophylactic effect on the occurrence and severity of pouchitis: a randomized prospective study. BioMed Res Int 2014; 2014: 208064.
54. McFarland LV. Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig Dis 1998; 16: 292-307.
55. Hempel S, Newberry SJ, Maher AR et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA 2012; 307: 1959-69.
56. Kale-Pradhan PB, Jassal HK, Wilhelm SM. Role of Lactobacillus in the prevention of antibiotic-associated diarrhea: a meta-analysis. Pharmacotherapy 2010; 30: 119-26.
57. Videlock EJ, Cremonini F. Meta-analysis: probiotics in antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2012; 35: 1355-69.
58. Laidman J. Probiotics Cut Antibiotic-Associated C diff Diarrhea by 66%: Medscape Medical News; 2012. http://www.medscape.com/viewarticle/774322 (accessed August 2014).
59. Leekha S, Aronhalt KC, Sloan LM, Patel R, Orenstein R. Asymptomatic Clostridium difficile colonization in a tertiary care hospital: admission prevalence and risk factors. Am J Infect Control 2013; 41: 390-3.
60. Johnston BC, Ma SS, Goldenberg JZ et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Ann Intern Med 2012; 157: 878-88.
61. Allen SJ, Wareham K, Wang D et al. Lactobacilli and Bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2013; 382: 1249-57.
62. Kalil AC, Schooneveld TC. Probiotics and antibiotic-associated diarrhoea. Lancet 2014; 383: 29-30.
63. Kogan M. Probiotics and antibiotic-associated diarrhoea. Lancet 2014; 383: 29.
64. Daneman N. A probiotic trial: tipping the balance of evidence? Lancet 2013; 382: 1228-30.
65. Besselink MG, van Santvoort HC, Buskens E et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371: 651-9.
66. Gou S, Yang Z, Liu T, Wu H, Wang C. Use of probiotics in the treatment of severe acute pancreatitis: a systematic review and meta-analysis of randomized controlled trials. Crit Care 2014; 18: R57.
67. Enache-Angoulvant A, Hennequin C. Invasive Saccharomyces infection: a comprehensive review. Clin Infect Dis 2005; 41: 1559-68.
68. Thygesen JB, Glerup H, Tarp B. Saccharomyces boulardii fungemia caused by treatment with a probioticum. BMJ Case Rep 2012, doi: 10.1136/bcr.06.2011.4412.
69. Knights D, Lassen KG, Xavier RJ. Advances in inflammatory bowel disease pathogenesis: linking host genetics and the microbiome. Gut 2013; 62: 1505-10.
70. Food and Drug Administration, 2014 [updated 20 June 2014]. Development and Approval Process (Drugs). http://www.fda.gov/Drugs/DevelopmentApprovalProcess/default.htm (accessed June 2014).
71. Roberfroid M, Gibson GR, Hoyles L et al. Prebiotic effects: metabolic and health benefits. Br J Nutr 2010; 104(Suppl 2): S1-63.
72. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 1995; 125: 1401-12.
73. Mangell P, Thorlacius H, Syk I et al. Lactobacillus plantarum 299v does not reduce enteric bacteria or bacterial translocation in patients undergoing colon resection. Dig Dis Sci 2012; 57: 1915-24.
74. Reddy BS, Macfie J, Gatt M, Larsen CN, Jensen SS, Leser TD. Randomized clinical trial of effect of synbiotics, neomycin and mechanical bowel preparation on intestinal barrier function in patients undergoing colectomy. Br J Surg 2007; 94: 546-54.
75. Gianotti L, Morelli L, Galbiati F et al. A randomized double-blind trial on perioperative administration of probiotics in colorectal cancer patients. World J Gastroenterol 2010; 16: 167-75.
76. Marteau P, Lemann M, Seksik P et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut 2006; 55: 842-7.
77. Van Gossum A, Dewit O, Louis E et al. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after ileo-caecal resection. Inflamm Bowel Dis 2007; 13: 135-42.
78. Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 2002; 51: 405-9.
79. Chermesh I, Tamir A, Reshef R et al. Failure of Synbiotic 2000 to prevent postoperative recurrence of Crohn's disease. Dig Dis Sci 2007; 52: 385-9.
80. Fedorak RN, Feagan BG, Hotte N et al. The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn's disease. Clin Gastroenterol Hepatol 2015; 13: 928-35.